IVVD

Invivyd Inc

0.9310

Aug 25 • 1:05 PM ET -0.0115 (-1.22%)

Healthcare Biotechnology USA Micro NASD

Peers: INCY BMRN KRYS KYMR RYTM CRNX AXSM MDGL VKTX NBIX

| Held by: IWM VTI IWN VXF IWC VTWO ITOT BBC PRFZ VTWV

Index	RUT
Market Cap	274.42M
Enterprise Value	122.73M
Income	-107.33M
Sales	58.37M
Book/sh	0.61
Cash/sh	0.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	122
IPO	Aug 06, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	4.70
P/B	1.52
P/C	1.71
P/FCF	-
EV/EBITDA	-
EV/Sales	2.10
Quick Ratio	5.86
Current Ratio	5.87
Debt/Eq	0.05
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-0.37
EPS next Y	-0.33
EPS next Q	-0.13
EPS this Y	-75.56%
EPS next Y	37.97%
EPS next 5Y	19.69%
EPS past 3/5Y	48.48% 12.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	59.47%
Sales Y/Y TTM	26.30%
EPS Q/Q	-13.34%
Sales Q/Q	21.20%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-31.21% -0.81%

Insider Own	15.81%
Insider Trans	-0.49%
Inst Own	77.67%
Inst Trans	-5.58%
ROA	-69.69%
ROE	-95.89%
ROIC	-57.14%
Gross Margin	88.78%
Oper. Margin	-192.81%
Profit Margin	-183.90%
SMA20	26.87%
SMA50	19.38%
SMA200	-39.30%
Trades

Shs Outstand	294.76M
Shs Float	248.15M
Short Float	11.20%
Short Ratio	6.07
Short Interest	27.80M
52W High	3.07 -69.67%
52W Low	0.52 80.08%
Volatility	13.70% 10.40%
ATR (14)	0.08
RSI (14)	62.49
Beta	0.78
Rel Volume	0.45
Avg Volume	4.58M
Volume	1,185,488

Perf Week	7.25%
Perf Month	52.65%
Perf Quarter	-15.36%
Perf Half Y	-44.91%
Perf YTD	-62.31%
Perf Year	66.34%
Perf 3Y	-49.95%
Perf 5Y	-96.67%
Perf 10Y	-
Recom	1.00
Target Price	10.00
Prev Close	0.94
Price	0.93
Change %	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-25	Initiated	BTIG Research	Buy	$10
Nov-25-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Aug-13-26 04:05PM	Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -6.33% +5.13%
Aug-04-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-06-26 01:39PM	IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 Invivyd Eyes Full FDA Approval (Stocktwits) -6.69%
07:01AM	Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA and Provides an Update on Next Steps with the U.S. FDA (GlobeNewswire)
Jul-02-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:01AM	Loading…
Jun-16-26 07:01AM	Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine (GlobeNewswire)
Jun-09-26 12:22PM	Invivyd doses first participants in Phase 3 COVID-19 trial (Proactive)
07:01AM	Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration (GlobeNewswire)
Jun-03-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-26 07:01AM	Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID (GlobeNewswire) +7.02%
May-27-26 07:01AM	Invivyd to Participate in Upcoming Investor Events (GlobeNewswire)
May-14-26 07:01PM	Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments (GuruFocus.com) -21.09%
07:01AM	Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-11-26 07:01AM	Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination (GlobeNewswire)
May-07-26 07:01AM	Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 (GlobeNewswire)
07:01AM	Loading…
May-05-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.44%
Apr-20-26 07:01AM	Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit (GlobeNewswire)
Apr-09-26 07:01AM	Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles (GlobeNewswire) +31.85%
Apr-07-26 07:01AM	Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health (GlobeNewswire)
Apr-06-26 07:01AM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 04:05PM	Invivyd Announces Presentation at the World Vaccine Congress Washington (GlobeNewswire) -13.14% +9.24%
Mar-05-26 09:07PM	Invivyd Q4 Earnings Call Highlights (MarketBeat)
04:02PM	Invivyd Inc (IVVD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
12:36PM	Invivyd, Inc. Q4 2025 Earnings Call Summary (Moby)
07:03AM	Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates (GlobeNewswire)
07:01AM	Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Mar-02-26 04:10PM	Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 (GlobeNewswire) -5.81%
04:01PM	Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 12:15PM	MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 07:01AM	New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies (GlobeNewswire)
05:10PM	Loading…
Feb-17-26 05:10PM	Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.45%
Feb-03-26 07:01AM	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration (GlobeNewswire) +8.05%
Jan-22-26 07:01AM	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention (GlobeNewswire)
Jan-20-26 07:01AM	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 (GlobeNewswire) -8.57%
Jan-14-26 02:13PM	?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 (Insider Monkey) +11.11%
Jan-08-26 07:01AM	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights (GlobeNewswire)
Dec-31-25 11:13AM	BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda (Insider Monkey)
Dec-23-25 07:05AM	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
07:01AM	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly) +25.22%
Dec-18-25 01:14AM	Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade (Insider Monkey)
Nov-25-25 07:01AM	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) -5.42%
Nov-24-25 07:01AM	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness (GlobeNewswire)
Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

M.B.A.Mr. William E. Duke Jr.

Chief Legal Officer & Corporate SecretaryMs. Jill Andersen J.D.

Chief Commercial OfficerMr. Timothy Lee

Chief Scientific OfficerDr. Robert D. Allen Ph.D.

Chief Communications OfficerMs. Kristie Coneys Kuhl J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Timothy Edward	Chief Commercial Officer	Aug 17 '26	Sale	0.72	22,355	16,140	197,362	Aug 18 08:10 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '26	Sale	0.84	18,425	15,530	178,937	Aug 18 08:10 PM
Green Julie	Chief Human Resources Officer	Aug 17 '26	Sale	0.72	22,355	16,140	187,362	Aug 18 08:10 PM
Green Julie	Chief Human Resources Officer	Aug 18 '26	Sale	0.84	18,425	15,530	168,937	Aug 18 08:10 PM
Duke William E.	Chief Financial Officer	Aug 17 '26	Sale	0.72	22,355	16,140	187,362	Aug 18 08:10 PM
Duke William E.	Chief Financial Officer	Aug 18 '26	Sale	0.84	18,425	15,530	168,937	Aug 18 08:10 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 17 '26	Sale	0.72	37,256	26,899	314,480	Aug 18 08:10 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '26	Sale	0.84	30,706	25,882	283,774	Aug 18 08:10 PM
Allen Robert D. III	Chief Scientific Officer	Aug 17 '26	Sale	0.72	20,679	14,930	195,808	Aug 18 08:10 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '26	Sale	0.84	17,043	14,366	178,765	Aug 18 08:10 PM
Lee Timothy Edward	Officer	Aug 17 '26	Proposed Sale	0.72	40,800	29,413		Aug 17 04:06 PM
Green Julie	Officer	Aug 17 '26	Proposed Sale	0.72	40,800	29,413		Aug 17 04:05 PM
Duke William E.	Officer	Aug 17 '26	Proposed Sale	0.72	40,800	29,413		Aug 17 04:05 PM
Andersen Jill	Officer	Aug 17 '26	Proposed Sale	0.72	68,001	49,022		Aug 17 04:05 PM
Allen Robert D. III	Officer	Aug 17 '26	Proposed Sale	0.72	37,741	27,207		Aug 17 04:05 PM
Allen Robert D. III	Chief Scientific Officer	Feb 18 '26	Sale	1.58	19,392	30,597	114,487	Feb 18 08:56 PM
Allen Robert D. III	Chief Scientific Officer	Feb 17 '26	Sale	1.54	18,189	28,004	133,879	Feb 18 08:56 PM
Green Julie	Chief Human Resources Officer	Feb 18 '26	Sale	1.58	20,964	33,077	107,717	Feb 18 08:51 PM
Green Julie	Chief Human Resources Officer	Feb 17 '26	Sale	1.54	19,663	30,273	128,681	Feb 18 08:51 PM
Duke William E.	Chief Financial Officer	Feb 18 '26	Sale	1.58	20,964	33,077	107,717	Feb 18 08:49 PM
Duke William E.	Chief Financial Officer	Feb 17 '26	Sale	1.54	19,663	30,273	128,681	Feb 18 08:49 PM
Lee Timothy Edward	Chief Commercial Officer	Feb 18 '26	Sale	1.58	20,964	33,077	117,717	Feb 18 08:47 PM
Lee Timothy Edward	Chief Commercial Officer	Feb 17 '26	Sale	1.54	19,663	30,273	138,681	Feb 18 08:47 PM
Andersen Jill	Chief Legal Officer, Secretary	Feb 18 '26	Sale	1.58	34,939	55,127	181,736	Feb 18 08:47 PM
Andersen Jill	Chief Legal Officer, Secretary	Feb 17 '26	Sale	1.54	32,771	50,454	216,675	Feb 18 08:47 PM
Green Julie	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:39 PM
Allen Robert D. III	Officer	Feb 17 '26	Proposed Sale	1.56	36,630	57,143		Feb 17 06:36 PM
Lee Timothy Edward	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:32 PM
Duke William E.	Officer	Feb 17 '26	Proposed Sale	1.56	39,600	61,776		Feb 17 06:30 PM
Andersen Jill	Officer	Feb 17 '26	Proposed Sale	1.56	66,000	102,960		Feb 17 06:26 PM
ADIMAB, LLC	10% Owner	Dec 23 '25	Proposed Sale	3.00	192,320	577,498		Dec 23 04:23 PM
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVVD

Invivyd Inc

Upgrade your Finviz experience